Compare Amphastar Pharmaceuticals Inc (AMPH) vs Newmont Corporation (NEM) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

Newmont Corporation (NEM) trades at $95.29, up 0.51% with bearish technical signals but strong fundamentals. The gold miner reported record Q1 2026 earnings of $2.90 EPS, beating estimates by 40%, with revenue growth accelerating to 46% year-over-year. Analyst consensus remains strongly bullish with 75% buy ratings and a $141 price target representing 48% upside. Cash flow generation reached $3.1 billion in Q1, supporting dividend payments and debt reduction.

Despite gold price volatility creating near-term pressure, Newmont's operational excellence and margin expansion support long-term value. The stock trades at attractive valuations (P/E 12.4x) with 34% net margins, though exposure to commodity cycles and recent technical weakness require careful risk management. The upcoming Q2 earnings on July 23 will be critical for confirming the growth trajectory.